Sensitizers for immunochromatographic assays and assay methods
A copolymer-based sensitizer enhances immunochromatographic methods to detect IgM and IgG antibodies of SARS-CoV-2 with high sensitivity, addressing the sensitivity issues in existing methods and facilitating early infection detection and treatment.
Patent Information
- Application Number
- JP2020207001
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-12-14
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2040-12-14
AI Technical Summary
Existing immunochromatographic methods for detecting IgM and IgG antibodies of the new coronavirus (SARS-CoV-2) lack sufficient sensitivity, leading to potential false negatives and delayed detection of infections.
A sensitizer comprising a copolymer with a specific alkyl group in its side chain is used in a sample diluent for immunochromatography, enhancing the antigen-antibody reaction to achieve high sensitivity in detecting IgM and IgG antibodies.
The method allows for the sensitive detection of IgM and IgG antibodies, enabling early identification of infections and facilitating timely treatment and prevention of COVID-19 spread.
Smart Images

Figure 0007589532000001 
Figure 0007589532000002 
Figure 0007589532000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a sensitizer for immunochromatographic assays in which novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies are the measurement target substances, and to an immunochromatographic assay in which novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies are the measurement target substances, performed in the presence of the sensitizer. [Background technology]
[0002] The immunochromatography method is a combination of a chromatographic method that utilizes the capillary action of a membrane and an immunological method that utilizes an antigen-antibody reaction. The immunochromatography method has high specificity due to the antigen-antibody reaction, is easy to operate, does not require space or special equipment, can be used for testing on the spot, and the results can be determined visually, so it is widely used as a clinical diagnostic method (Patent Document 1).
[0003] Although the immunochromatographic method has the advantage of being easy to perform, the detection sensitivity is low and a positive sample may be judged as a false negative, so that a more sensitive immunochromatographic method is desired.
[0004] To date, various methods have been investigated with the aim of establishing a highly sensitive immunochromatographic measurement method, for example, Patent Document 2 discloses a method of increasing sensitivity by changing the position at which an immunochromatographic reagent is added, and Patent Document 3 discloses a method of increasing sensitivity by improving the membrane material.
[0005] Furthermore, a method is known in which an additive is added to the specimen dilution solution used in the conventional immunochromatography to achieve high sensitivity. For example, Patent Documents 4, 5, and 6 disclose that the specimen dilution solution contains bovine serum albumin (BSA), a polymer having a phosphorylcholine group, and hyaluronic acid. These disclosures have the advantage that there is no need to change the position where the reagent is added, and that conventional immunochromatography membranes can be used.
[0006] However, the above patent documents do not disclose or suggest any sensitizers to be used in a method for measuring novel coronavirus (SARS-CoV-2) IgM antibodies and IgG antibodies with high sensitivity.
[0007] In particular, SARS-CoV-2 IgM antibodies are produced early in infection with SARS-CoV-2, and if IgM antibodies can be detected with high sensitivity, infected individuals can be isolated at an early stage of infection, making it possible to prevent the spread of infection. In addition, sensitizers that can detect IgM antibodies with high sensitivity are thought to be highly useful, as they can be used to start treatment early and improve the effectiveness of treatment.
[0008] Furthermore, IgG antibodies to the novel coronavirus (SARS-CoV-2) are produced in the body for a long period of time, and if IgG antibodies could be detected with high sensitivity, it would be possible to identify infected individuals in the later stages of infection. In identifying infected individuals with the novel coronavirus, many of whom are unaware of their infection, a sensitizer that can detect IgG antibodies produced over a long period of time with high sensitivity is thought to be highly useful. [Prior art documents] [Patent documents]
[0009] [Patent Document 1] Japanese Patent Application Publication No. 01-063865 [Patent Document 2] JP 2014-66674 A [Patent Document 3] JP 2014-62820 A [Patent Document 4] JP 2008-292326 A [Patent Document 5] JP 2008-058334 A [Patent Document 6] JP 2003-344413 A Summary of the Invention [Problem to be solved by the invention]
[0010] The present invention aims to provide a sensitizer for immunochromatographic assays that can detect novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies with high sensitivity, and a measurement method using the sensitizer. [Means for solving the problem]
[0011] The inventors conducted intensive research to find a compound capable of detecting novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies with high sensitivity, and as a result, discovered that a copolymer having a group in its side chain that has a phosphorylcholine-like group, as shown in the following general formula [1], has the desired performance, thereby completing the present invention.
[0012] That is, the present invention comprises the following. [1] A sensitizer for immunochromatographic measurement using novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies as the measurement target substance, comprising a compound represented by the following general formula [1]:
[0013] [ka]
[0014] (In the formula, n represents 0 or 1, and R represents an alkyl group having 6 to 16 carbon atoms.) [2] A sample dilution solution for immunochromatographic assays in which the target substance to be measured is novel coronavirus (SARS-CoV-2) IgM antibody and / or IgG antibody, containing the sensitizer for immunochromatographic assays described in [1]. [3] An immunochromatographic assay for measuring novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies, characterized by carrying out an antigen-antibody reaction in the presence of the sensitizer for immunochromatographic assay described in [1]. [4] An immunochromatographic measurement device for measuring novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies as the measurement target substance, comprising the sensitizer for immunochromatographic measurement described in [1]. [5] A kit for testing for novel coronavirus disease (COVID-19), comprising the sensitizer for immunochromatographic assay described in [1] and a substance that specifically binds to novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies. [6] A method for testing whether a subject may be infected with the novel coronavirus disease 2019 (COVID-19), comprising measuring novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies in a biological sample from the subject by carrying out an antigen-antibody reaction in the presence of the sensitizer for immunochromatographic assay described in [1]. [7] A method for treating novel coronavirus disease (COVID-19), comprising the steps of (1) and (2) below: (1) A step of measuring the novel coronavirus (SARS-CoV-2) by carrying out an antigen-antibody reaction in the presence of a sensitizer for immunochromatographic measurement comprising a compound represented by the following general formula [1]; and (2) A process of administering treatment for coronavirus disease 2019 (COVID-19) to patients based on the measurement results in (1) above.
[0015] [ka]
[0016] (In the formula, n represents 0 or 1, and R represents an alkyl group having 6 to 16 carbon atoms.) [8] A kit for treating novel coronavirus disease (COVID-19), comprising a sensitizer for immunochromatographic measurement comprising a compound represented by the following general formula [1] and a therapeutic agent for novel coronavirus disease (COVID-19).
[0017] [ka]
[0018] (In the formula, n represents 0 or 1, and R represents an alkyl group having 6 to 16 carbon atoms.) Effect of the Invention
[0019] The measurement method of the present invention uses a sensitizer for immunochromatographic measurement with novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies as the measured substance, and can detect novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies with higher sensitivity than conventional immunochromatographic measurement methods that detect novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0020] The following describes the present invention's sensitizer for immunochromatographic measurement using novel coronavirus (SARS-CoV-2) IgM antibody and / or IgG antibody as the measurement target, a specimen dilution solution for immunochromatographic measurement using the above antibody containing the sensitizer as the measurement target, an immunochromatographic measurement using the above antibody as the measurement target which causes an antigen-antibody reaction in the presence of the sensitizer, an immunochromatographic measurement instrument using the above antibody containing the sensitizer as the measurement target, and a method for treating novel coronavirus disease (COVID-19) which includes a step of causing an antigen-antibody reaction in the presence of the sensitizer.
[0021] In the measurement method using the immunochromatographic measurement sensitizer of the present invention, the substance to be measured is the novel coronavirus (SARS-CoV-2) IgM antibody and / or IgG antibody, but other substances to be measured can also be detected. However, the immunochromatographic measurement sensitizer of the present invention is characterized by its ability to detect the above-mentioned antibodies with high sensitivity.
[0022] As used herein, novel coronavirus refers to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a strain of coronavirus that causes COVID-19 (also known as coronavirus disease 2019), the respiratory illness that has led to the COVID-19 pandemic. Each SARS-CoV-2 virion is 50-200 nanometers in diameter, and like other coronaviruses, SARS-CoV-2 has four structural proteins known as the S (spike), E (envelope), M (membrane), and N (nucleocapsid) proteins. The N protein carries the RNA genome, and the S, E, and M proteins together form the viral envelope. The spike protein is a protein that allows the virus to attach to and fuse with the membrane of a host cell. SARS-CoV-2 is transmitted from human to human, and transmission was initially assumed to occur primarily via respiratory droplets from coughs and sneezes within a certain range. It has also been suggested that the virus may also be airborne, as aerosols can transmit the virus.
[0023] The compound used as a sensitizer for the immunochromatographic measurement method of the present invention in which the novel coronavirus is the measurement target substance is represented by the following general formula [1].
[0024] [ka]
[0025] (In the formula, n represents 0 or 1, and R represents an alkyl group having 6 to 16 carbon atoms.)
[0026] n is preferably 1. The "alkyl group having 6 to 16 carbon atoms" in R means a straight-chain or branched-chain alkyl group having 6 to 16 carbon atoms, and specific examples thereof include a hexyl group, a 4-methylpentyl group, a 1-methylpentyl group, a heptyl group, an octyl group, a 6-methylheptyl group, a 1-methylheptyl group, a nonyl group, a decyl group, an 8-methylnonyl group, a 1-methylnonyl group, an undecyl group, a dodecyl group, a 10-methylundecyl group, a 1-methylundecyl group, a tridecyl group, a tetradecyl group, a hexadecyl group, etc. Among these, an alkyl group having 6 to 12 carbon atoms is preferable, and an alkyl group having 10 to 12 carbon atoms is more preferable.
[0027] Preferred examples of the compound used as a sensitizer for immunochromatographic assay include those described in the following Examples, but are not particularly limited thereto.
[0028] The compound used as a sensitizer for immunochromatographic assay of the present invention may be dissolved in various reagents or samples used in immunochromatographic assay, or may be supported on an immunochromatographic assay kit, but is preferably used as a specimen diluent.
[0029] In the immunochromatographic assay of the present invention, the immunochromatographic assay kit used generally comprises a specimen dilution solution and a test strip.
[0030] The specimen diluent is a suitable diluent for measurement by the immunochromatography method, and may contain buffer components such as Tris buffer, phosphate buffer, veronal buffer, borate buffer, Good's buffer, etc., stabilizing components such as albumin, globulin, casein, serum, water-soluble gelatin, surfactants, sugars, chelating agents, etc., and preservative components such as salicylic acid, benzoic acid, sodium azide, etc.
[0031] When the sensitizer of the present invention is used by dissolving it in a specimen diluent, the concentration thereof as the concentration at which the antigen-antibody reaction takes place is not particularly limited, but is usually used at 0.1 to 5.0 w / v%, preferably 0.5 to 1.0 w / v%.
[0032] A test strip generally comprises at least a first substance capable of undergoing an antigen-antibody reaction with a first antigenic determinant of a specimen, a labeled second substance capable of undergoing an antigen-antibody reaction with a second antigenic determinant of the specimen, and a membrane carrier, the first substance being fixed in advance at a predetermined position on the membrane carrier to form a capture site, and the second substance being arranged at a position separated from the capture site so as to be capable of chromatographic development on the carrier. In one embodiment, when the specimen is an antibody (including an IgM antibody and / or an IgG antibody), the first substance and / or the second substance may be an antigen for the antibody.
[0033] The immunochromatographic test strip may be a commercially available product or may be prepared by a known method. When prepared by a known method, the base material used in the spreading membrane may be one that is generally used in this field, and examples of preferred materials include cellulose, nitrocellulose, nylon, and the like.
[0034] Immunochromatographic measurement devices for measuring novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies containing the sensitizer of the present invention include, for example, but are not limited to, (1) devices consisting of a developing membrane, (2) devices consisting of a specimen labeling portion and a developing membrane, and formed so that the specimen labeling portion and the developing membrane can move by capillary action, (3) devices consisting of a specimen labeling portion, a developing membrane, and a liquid absorbing portion, and formed so that the specimen labeling portion, the developing membrane, and the liquid absorbing portion can move in this order by capillary action, and (4) devices consisting of a specimen dropping portion, a specimen labeling portion, a developing membrane, and a liquid absorbing portion, and formed so that the specimen dropping portion, the specimen labeling portion, the developing membrane, and the liquid absorbing portion can move in this order by capillary action.
[0035] When the sensitizer of the present invention is used by being supported on the immunochromatographic measurement device, the amount of the sensitizer varies depending on the location of support, the type of sensitizer used, the type of the substance to be measured used, the labeling substance used, and the like. For example, when the sensitizer is supported on the developing membrane, the sample labeling section, the sample dropping section, and the like of the immunochromatographic measurement device, the amount of the sensitizer per unit area (cm 2 The amount of sensitizer contained per unit area is usually 0.01 μg to 10 mg, preferably 0.1 μg to 4 mg, and more preferably 1 to 800 μg. The supported area varies depending on the type and size of the immunochromatographic measurement device used and the amount of the measurement sample, but in the case of the developing membrane of the immunochromatographic measurement device, it is usually 5 to 60% of the total area, preferably 5 to 15%, and in the case of the sample dropping portion, it is usually 5 to 40% of the total area, preferably 10 to 20%.
[0036] The present invention provides a kit for testing for novel coronavirus disease (COVID-19), which comprises the sensitizer for immunochromatographic assay of the present invention and a substance that specifically binds to novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies.
[0037] "Specific" means that the affinity for the novel coronavirus (SARS-CoV-2) IgM and / or IgG antibodies is higher than the affinity for other substances (in one embodiment, IgM and / or IgG antibodies against antigens other than the novel coronavirus (SARS-CoV-2) proteins are not included in the "other substances"). The specifically binding substance has, for example, about 10 -6 , 10 -7 , 10 -8 , 10 -9 , 10 -10 The substance binds to the novel coronavirus (SARS-CoV-2) IgM antibody and / or IgG antibody with a KD of 10 -14 , 10 -13 , 10 -12 It binds to novel coronavirus (SARS-CoV-2) IgM and / or IgG antibodies with a KD equal to or greater than this value.
[0038] The substance is preferably isolated or purified. "Isolated or purified" means that a procedure has been performed to remove components other than the target component from a natural state. The purity of the isolated or purified substance (the ratio of the weight of the substance to the total protein weight) is usually 50% or more, preferably 70% or more, more preferably 90% or more, and most preferably 95% or more (e.g., substantially 100%).
[0039] The substance may be directly or indirectly labeled with a labeling substance. Examples of the labeling substance include fluorescent substances (e.g., FITC, rhodamine), radioactive substances (e.g., 14 C. 3 H, 125 I), enzymes (eg, alkaline phosphatase, peroxidase), colored particles (eg, metal colloid particles, colored latex), biotin, etc.
[0040] In the present invention, examples of "substances that specifically bind to novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies" include antigens against novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies, antibodies that specifically bind to novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies, nucleic acids (e.g., aptamers), etc., with antigens against novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies, and anti-new coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies being preferred.
[0041] The antigen is not limited to any antigen against the novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies that are the subject of measurement in the present invention, but examples include novel coronavirus S (spike) protein, E (envelope) protein, M (membrane) protein, and N (nucleocapsid) protein.
[0042] When a recombinant SARS-CoV-2 protein is used as an antigen, the recombinant SARS-CoV-2 protein can be produced, for example, by the following method. A polynucleotide encoding the amino acid sequence of the SARS-CoV-2 protein is incorporated into an appropriate expression vector, which is then inserted into an appropriate host for transformation, and the desired recombinant SARS-CoV-2 protein can be obtained from the disruption of the transformed cells. The host cells are not particularly limited, and various host cells that have been conventionally used in genetic engineering techniques, such as Escherichia coli, Bacillus subtilis, yeast, plant or animal cells, can be used.
[0043] The novel coronavirus (SARS-CoV-2) protein may be a recombinant protein produced by the transformant, or may be isolated or purified from the natural novel coronavirus (SARS-CoV-2) that produces it by a known protein separation and purification technique. It may also be a protein that is chemically synthesized or biochemically synthesized in a cell-free translation system.
[0044] In one aspect, the above-mentioned "anti-novel coronavirus (SARS-CoV-2) IgM antibody and / or IgG antibody" includes anti-IgM antibody and / or anti-IgG antibody from an animal of the same species as the animal that produced the IgM antibody and / or IgG antibody.
[0045] The antibody may be of any isotype, e.g., IgA, IgD, IgE, IgG (e.g., IgG1, IgG2, IgG3, or IgG4), IgM, etc. The antibody may be a polyclonal antibody, a monoclonal antibody, a chimeric antibody, or a single-chain antibody. The antibody may also be a portion of an antibody (antibody fragment) that has antigen-binding ability, such as a Fab fragment or a fragment produced by a Fab expression library. Examples of antibody fragments include (i) a Fab fragment, which is a monovalent fragment consisting of the VL, VH, CL, and CH1 domains, and (ii) an F(ab') fragment, which is a bivalent fragment containing two Fab fragments linked by a disulfide bridge at the hinge region. 2(iii) an Fv fragment consisting of the VL and VH domains of a single arm of an antibody; and (iv) an F(ab') fragment produced by mild reducing conditions. 2 Examples of such fragments include, but are not limited to, (a) Fab' fragments obtained by disrupting the disulfide bridges of the fragments, (b) disulfide-stabilized Fv fragments (dsFv), and (c) domain antibodies (dAbs), which are single variable region domain (VH or VL) polypeptides of an antibody that specifically binds to an antigen.
[0046] The anti-new coronavirus (SARS-CoV-2) IgM and / or IgG antibodies used in the method of the present invention may be produced in mice, guinea pigs, hamsters, goats, or rabbits. In addition, the anti-new coronavirus (SARS-CoV-2) IgM and / or IgG antibodies may be commercially available.
[0047] The testing kit of the present invention contains the above-mentioned sensitizer for the immunochromatographic assay of the present invention and a substance that specifically binds to novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies in separate containers.
[0048] Furthermore, the testing kit of the present invention may include instructions stating that the immunochromatographic assay sensitizer of the present invention and a substance that specifically binds to novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies can be or should be used to test for novel coronavirus disease (COVID-19).
[0049] The COVID-19 test kit may include any carrier, such as a medicamentically acceptable carrier, a stabilizer or buffer component, other therapeutic agents, supplements, etc. Examples of medicamentically acceptable carriers include, but are not limited to, diluents such as water and saline. The COVID-19 test kit of the present invention may also include a specimen diluent, a test strip for immunochromatography measurement, and an instrument for immunochromatography measurement.
[0050] The present invention provides a method for testing the possibility that a subject is infected with novel coronavirus disease (COVID-19), comprising measuring novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies in a biological sample derived from the subject by performing an antigen-antibody reaction in the presence of the sensitizer for immunochromatographic assay of the present invention.
[0051] Biological samples that can be used in this method include blood, but are not particularly limited as long as they can detect novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies. Although "blood" can be blood derived from any tissue, peripheral blood is usually used because of its ease of collection. A method known per se can be applied as a method for collecting blood. The collected blood may be used in this method as is, or may be used in this method as a liquid component (plasma) from which cellular components (red blood cells, white blood cells, platelets, etc.) have been separated using a method known per se, such as centrifugation or filtration. It is also possible to use in this method as a liquid component (serum) from which platelets and coagulation factors have been separated by coagulating the blood.
[0052] In carrying out the test method of the present invention, for example, a biological sample of a subject such as blood is suspended in an extraction solution, and antigens are extracted from the biological sample solution. Then, for example, when using the immunochromatographic measurement device described above in (4), the biological sample solution treated with the extraction solution is dropped into the sample dropping section. In this way, in the presence of the immunochromatographic measurement sample dilution solution containing the immunochromatographic measurement sensitizer of the present invention, the biological sample solution is developed from the sample dropping section to the sample labeling section and onto the membrane by capillary action.
[0053] When the target antigen in the biological sample liquid (e.g., novel coronavirus (SARS-CoV-2) IgM antibody and / or IgG antibody) passes through the sample labeling section, it forms an immune complex with the labeled substance (e.g., anti-severe coronavirus (SARS-CoV-2) IgM antibody and / or IgG antibody) carried by the sample labeling section, and is spread as it is to one end of the spreading membrane. Then, the complex and the substance (e.g., antigen against novel coronavirus (SARS-CoV-2) IgM antibody and / or IgG antibody) present on the test line of the spreading membrane (coated on the test line) undergo an immunochemical reaction and bind, causing coloration and a visible line to appear on the spreading membrane. When coloration occurs in this way, the sample is positive, and if the target antigen in the biological sample liquid is novel coronavirus (SARS-CoV-2) IgM antibody, it can be determined that the subject is infected with novel coronavirus (COVID-19). If the target antigen in the biological sample liquid is novel coronavirus (SARS-CoV-2) IgG antibody, it can be determined that the subject is infected with novel coronavirus (COVID-19) or has been infected in the past. The intensity of the positive result can be determined by visual inspection or by measuring the degree of coloration with an appropriate analytical device (e.g., an immunochromatograph, a spectrophotometer). When, for example, a fluorescent dye is used as the detection means possessed by the labeled antibody, the test line can be irradiated with ultraviolet light or the like, and the presence or absence of coloration and the degree of coloration can be used to determine whether or not the result is positive.
[0054] On the other hand, there is a control line after the test line, and the antibodies present there (coated there) undergo an immunochemical reaction with the labeled substance that has not formed an immune complex (e.g., anti-novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies), which binds and turns color, allowing visual confirmation that the immunochromatography was performed without any problems.
[0055] After the specimen sample liquid spreads over the spreading membrane, the unreacted labeled antibodies, etc. are absorbed by the absorbent pad. If the specimen does not contain the target antigen (e.g., SARS-CoV-2 IgM and / or IgG antibodies), the test line will not turn colored, and only the control line will turn colored. In this case, the specimen is negative, and if the target antigen in the biological specimen liquid is SARS-CoV-2 IgM antibody, the subject is not determined to be infected with COVID-19. If the target antigen in the biological specimen liquid is SARS-CoV-2 IgG antibody, the subject is not determined to be infected with COVID-19, nor is it determined that he or she was infected in the past.
[0056] In one embodiment, if the target antigen in the biological sample liquid is a novel coronavirus (SARS-CoV-2) IgM antibody and the target antigen in the biological sample liquid is a novel coronavirus (SARS-CoV-2) IgG antibody, the subject is not determined to be infected with COVID-19 or to have been infected in the past. If the target antigen in the biological sample liquid is a novel coronavirus (SARS-CoV-2) IgM antibody and the target antigen in the biological sample liquid is a novel coronavirus (SARS-CoV-2) IgG antibody, the subject is determined to be infected with COVID-19 and to be in the early stage of infection. If the target antigen in the biological sample liquid is a novel coronavirus (SARS-CoV-2) IgM antibody and the target antigen in the biological sample liquid is a novel coronavirus (SARS-CoV-2) IgG antibody, the subject is determined to be infected with COVID-19 and to have been infected for a certain period of time. If the target antigen in the biological sample liquid is a novel coronavirus (SARS-CoV-2) IgM antibody and the test result is negative, and if the target antigen in the biological sample liquid is a novel coronavirus (SARS-CoV-2) IgG antibody and the test result is positive, it can be determined that the subject is infected with novel coronavirus disease (COVID-19).
[0057] The biological sample to be subjected to the testing method of the present invention is a sample derived from a mammalian subject. The mammal is not particularly limited as long as it is a mammal that may be infected with novel coronavirus disease (COVID-19), but among them, preferred are laboratory animals such as rodents such as mice, rats, hamsters, and guinea pigs, and rabbits, livestock such as pigs, cows, goats, horses, sheep, and minks, pets such as dogs and cats, and primates such as humans, monkeys, cynomolgus monkeys, rhesus monkeys, marmosets, orangutans, and chimpanzees, and particularly preferred are humans.
[0058] The method for treating novel coronavirus disease (COVID-19) of the present invention comprises at least the following steps (1) and (2). (1) A process for measuring the novel coronavirus (SARS-CoV-2) by carrying out an antigen-antibody reaction in the presence of a sensitizer for immunochromatographic measurement comprising a compound. (2) A process of administering treatment for coronavirus disease 2019 (COVID-19) to patients based on the measurement results in (1) above.
[0059] The term "patients" also includes people who may be infected with the novel coronavirus (SARS-CoV-2). Measurement refers to detecting the presence of novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies in a patient-derived sample.
[0060] In addition, the process of treating patients with COVID-19 includes not only administering known therapeutic drugs, therapeutic drugs that will be launched in the future, and candidate therapeutic drugs in the clinical stage to patients, but also symptomatic treatments (administration of aspirin, fluid replacement, transfusion, etc.).
[0061] The treatment method for novel coronavirus disease 2019 (COVID-19) of the present invention can detect novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies with high sensitivity, enabling novel coronavirus disease 2019 (COVID-19) patients to be rapidly treated for novel coronavirus disease 2019 (COVID-19).
[0062] Symptoms of novel coronavirus disease (COVID-19) range from asymptomatic to severe pneumonia and death, but specific symptoms include fever, dry cough, fatigue, lethargy, phlegm, loss of smell and taste, shortness of breath, muscle and joint pain, sore throat, headache, chills, nausea, vomiting, nasal congestion, diarrhea, hemoptysis, and conjunctival congestion.
[0063] In another aspect, the method for treating novel coronavirus disease (COVID-19) of the present invention comprises at least the following steps (1) and (2). (1) A process for measuring the novel coronavirus (SARS-CoV-2) by carrying out an antigen-antibody reaction in the presence of a sensitizer for immunochromatographic measurement comprising the compound. (2) A process of administering treatment for coronavirus disease 2019 (COVID-19) to subjects other than humans based on the measurement results of (1) above.
[0064] The subject other than human to be subjected to the treatment method of the present invention is not limited, but preferably means a mammal. More preferably, the mammal includes a mammal that may be infected with novel coronavirus disease (COVID-19), and among them, preferred are laboratory animals such as rodents such as mice, rats, hamsters, and guinea pigs, and rabbits, livestock such as pigs, cows, goats, horses, sheep, and minks, pets such as dogs and cats, and primates such as monkeys, cynomolgus monkeys, rhesus monkeys, marmosets, orangutans, and chimpanzees.
[0065] The present invention provides a kit for treating novel coronavirus disease (COVID-19), comprising a sensitizer for immunochromatographic assay comprising the compounds represented by the above formulas [1] and [2], and a therapeutic agent for novel coronavirus disease (COVID-19).
[0066] The therapeutic agent may be, for example, a therapeutic agent for novel coronavirus disease (COVID-19), and examples of the therapeutic agent include, but are not limited to, remdesivir, dexamethasone, favipiravir (Avigan), ciclesonide, nafamostat, camostat, ivermectin, nelfinavir, etc. The therapeutic agent may be tocilizumab, baricitinib, acalabrutinib, ravipiravir, eritoran, ibudilast, LY3127804, otilimab, HLCM051, ADR-001, icatibant, apremilast, or cenicriviroc, which are therapeutic agents for severe pneumonia or acute respiratory distress syndrome. The therapeutic agent may be a therapeutic agent to be marketed in the future or a candidate therapeutic agent in the clinical stage. The therapeutic agent may be aspirin, fluid replacement, infusion, etc., which are used for symptomatic treatment.
[0067] The treatment kit of the present invention contains the above-mentioned sensitizer for immunochromatographic assay of the present invention and a treatment for novel coronavirus disease (COVID-19) in separate containers.
[0068] Furthermore, the treatment kit of the present invention may include instructions stating that the sensitizer for immunochromatographic assay and the treatment kit for novel coronavirus disease (COVID-19) of the present invention can be or should be used for the treatment of novel coronavirus disease (COVID-19).
[0069] The above-mentioned COVID-19 treatment kit may include any carrier, such as a medicamentically acceptable carrier, a stabilizer or buffer component, other therapeutic agents, supplements, etc. Examples of medicamentically acceptable carriers include, but are not limited to, diluents such as water and saline. In addition, the COVID-19 treatment kit of the present invention may include a specimen diluent, a test strip for immunochromatographic measurement, and an instrument for immunochromatographic measurement.
[0070] The therapeutic kit of the present invention may further contain a substance that specifically binds to novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies.
[0071] The novel coronavirus disease (COVID-19) treatment kit of the present invention can detect novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies with high sensitivity, enabling novel coronavirus disease (COVID-19) treatment to be rapidly administered to subjects (patients) with novel coronavirus disease (COVID-19).
[0072] The present invention will be described in more detail below with reference to the following examples, but the present invention is not limited to these examples. EXAMPLES
[0073] Manufacturing Example (Synthesis of copolymers of the present invention and comparative examples) The compounds used as sensitizers for immunochromatographic assays of the present invention were synthesized as follows.
[0074] The compound used in the present invention is a compound containing a phosphorylcholine group as shown in the above chemical formula [1]. (Compound 1) In the above chemical formula (1), n is 1 and R is a hexyl group. (Compound 2) In the above chemical formula (1), n is 1 and R is an octyl group. (Compound 3) In the above chemical formula (1), n is 1 and R is a decyl group. (Compound 4) In the above chemical formula (1), n is 1 and R is a dodecyl group. (Compound 5) In the above chemical formula (1), n is 0 and R is a hexadecyl group.
[0075] Working Example (Confirmation of detection sensitivity using known immunochromatographic measurement equipment) In this example, it was confirmed whether the above polymer can improve the detection sensitivity (sensitization effect) of a known detection kit for novel coronavirus (SARS-CoV-2) IgM antibody and / or IgG antibody. Details are as follows.
[0076] (Comparative Example) The evaluation was performed using a commercially available SARS-CoV-2 IgM antibody detection kit and a SARS-CoV-2 IgG antibody detection kit (both manufactured by RayBiotec.). More specifically, 25 μL of serum from a patient positive for the new coronavirus (CoV-PosM-S-100, manufactured by RayBiotec.) was added to 245 μL of diluted solution from the SARS-CoV-2 IgM antibody detection kit or the SARS-CoV-2 IgG antibody detection kit, and the diluted solution was developed in an immunochromatography kit.
[0077] (Example) Compounds 1, 2, 3, 4 or 5 were added to the dilution solution of the kit to a final concentration of 0.5% by weight, and a solution prepared so that the serum of a coronavirus-positive patient was 100-fold diluted compared to the comparative example was developed, and the detection sensitivity was compared.
[0078] (Results of confirming the sensitivity of IgM antibody detection using immunochromatographic measurement equipment) The results of improving detection sensitivity using a known novel coronavirus (SARS-CoV-2) IgM antibody detection kit are shown in Table 1.
[0079] [Table 1]
[0080] When 0.5 wt % of polymer 1, 2, 3, 4 or 5 was added, a test line for IgM antibody was detected that was equal to or more intense than that of the control (comparison example), or slightly fainter, confirming that the addition of copolymer 1, 2, 3, 4 or 5 improved the sensitivity.
[0081] (Results of confirming the sensitivity of IgG antibody detection using immunochromatographic measurement equipment) The results of improving detection sensitivity using a known novel coronavirus (SARS-CoV-2) IgG antibody detection kit are shown in Table 2.
[0082] [Table 2]
[0083] When 0.5 wt % of polymer 1, 2, 3, 4 or 5 was added, a test line was detected for the IgG antibody that was equal to or more intense than that of the control (comparative example), or slightly less intense. This confirmed that the addition of copolymer 1, 2, 3, 4 or 5 improved the sensitivity.
[0084] From the above examples, it is apparent that the present invention provides an immunochromatographic assay method that has a significantly superior sensitivity enhancement effect compared to known immunochromatographic assay methods that use novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies as the measured substance.
[0085] As is clear from the above, the present invention has provided an immunochromatographic assay method having a superior sensitivity enhancement effect compared to known immunochromatographic assay methods in which novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies are used as the measured substance.
[0086] Furthermore, the treatment method for novel coronavirus disease (COVID-19) of the present invention can detect the novel coronavirus (SARS-CoV-2) with high sensitivity, and therefore can rapidly administer treatment for novel coronavirus disease (COVID-19) to patients with novel coronavirus disease (COVID-19) or patients who may be infected with the novel coronavirus (SARS-CoV-2), resulting in a high therapeutic effect. [Industrial Applicability]
[0087] The present invention can provide a sensitizer for immunochromatographic assays in which novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies are used as the measurement target substances.
Claims
1. A sensitizer for immunochromatographic measurement in which a novel coronavirus (SARS-CoV-2) IgM antibody and / or IgG antibody is the measurement target substance, comprising a compound represented by the following general formula [1]: [Case 1] (In the formula, n represents 0 or 1, and R represents an alkyl group having 6 to 16 carbon atoms.)
2. A sample dilution solution for immunochromatographic assay in which a novel coronavirus (SARS-CoV-2) IgM antibody and / or IgG antibody is the substance to be measured, comprising the sensitizer for immunochromatographic assay according to claim 1.
3. An immunochromatographic assay method for measuring novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies as the measurement target substance, characterized by carrying out an antigen-antibody reaction in the presence of the sensitizer for immunochromatographic assay according to claim 1.
4. An immunochromatographic measurement device for measuring novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies as a measurement target substance, comprising the sensitizer for immunochromatographic measurement according to claim 1.
5. A kit for testing for novel coronavirus disease (COVID-19), comprising the sensitizer for immunochromatographic assay according to claim 1 and a substance that specifically binds to novel coronavirus (SARS-CoV-2) IgM antibodies and / or IgG antibodies.
6. A method for testing the possibility that a subject is infected with novel coronavirus disease (COVID-19), comprising measuring novel coronavirus (SARS-CoV-2) IgM antibody and / or IgG antibody in a biological sample derived from the subject by carrying out an antigen-antibody reaction in the presence of the sensitizer for immunochromatographic assay according to claim 1.
7. A kit for treating COVID-19, comprising a sensitizer for immunochromatographic assay comprising a compound represented by the following general formula [1] and a therapeutic agent for COVID-19. [Case 2] (In the formula, n represents 0 or 1, and R represents an alkyl group having 6 to 16 carbon atoms.)
Citation Information
Patent Citations
Kit for combined detection of 2019 novel coronavirus IgM and IgG antibodies and preparation method thereof
CN111426831A
Solid phase immunoassay
JP1989063865A
Developing solvent for immuno-chromatography, measuring method and kit
JP2003344406A
Sensitivity enhancing agent for immuno-chromatographic measuring method, measuring method and apparatus for measuring method
JP2003344413A
Development solvent, measuring method and kit for immunochromatography
JP2008058334A
